After psilocybin, Parkinson's patients' inflammation fell — and stayed down for a month

In a small pilot study at the University of California, San Francisco, 12 people with Parkinson's disease took psilocybin in two sessions — and blood tests afterwards showed five inflammation signals had dropped significantly, with the change still visible a month later. The results, published in JAMA Psychiatry, are among the first human evidence that psychedelics may calm inflammation across the body, not just shift the mind. The team stresses the study was small and had no control group — but outside experts call it an exciting proof of principle.

SDG 3 · Good health and well-being — Mechanism: tech innovation